Mirum Pharmaceuticals Inc(MIRM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:08 PM ET (Korea 10/31 05:08)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -14.55 | Insider Own | 17.16% | Shs Outstand | 64.8M | Perf Week | 5.73% |
| Market Cap | 5.52B | Forward P/E | - | EPS next Y | 95.82% | Insider Trans | -1.59% | Shs Float | 53.8M | Perf Month | 1.29% |
| Enterprise Value | 5.84B | PEG | - | EPS next Q | -0.49 | Inst Own | 94.67% | Short Float | 12.39% | Perf Quarter | -18.73% |
| Income | -0.86B | P/S | 8.93 | EPS this Y | -3117.63% | Inst Trans | 4.48% | Short Ratio | 9.26 | Perf Half Y | -11.94% |
| Sales | 0.62B | P/B | - | EPS next 5Y | - | ROA | -97.15% | Short Interest | 6.66M | Perf YTD | 7.61% |
| Book/sh | -0.16 | P/C | 12.59 | EPS past 3/5Y | 51.26% 35.25% | ROE | -702.97% | 52W High | -34.62% ($130.00) | Perf Year | 17.73% |
| Cash/sh | 6.75 | P/FCF | - | Sales past 3/5Y | 89.13% - | ROIC | -114.68% | 52W Low | 34.43% ($63.23) | Perf 3Y | 211.93% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1101.02% | Gross Margin | 81.65% | Volatility(W/M) | 3.68% 4.5% | Perf 5Y | 435.26% |
| Dividend TTM | - | EV/Sales | 9.46 | Sales Y/Y TTM | 44.02% | Oper. Margin | -14.76% | ATR (14) | 3.6 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.74 | EPS Q/Q | -799.75% | Profit Margin | -139.18% | RSI (14) | 48.69 | Recom | 1.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.86 | Sales Q/Q | 37.92% | SMA20 | 2.59% ($82.85) | Beta | 0.75 | Target Price | $153.43 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/3 | SMA50 | -5.48% ($89.93) | Rel Volume | 0.94 | Prev Close | $86.39 |
| Employees | 372 | LT Debt/Eq | - | EPS/Sales Surpr. | -42.76% 5.93% | SMA200 | -13.77% ($98.57) | Avg Volume(3M) | 0.72M | Price | $85 |
| IPO | 2019/7/18 | Option/Short | Yes/Yes | Trades | 9942 | Volume | 673,448 | Change | -1.61% |
🧬 This is a commercial-stage biotech company that develops and sells treatments for rare liver diseases. It generates revenue by selling a treatment for rare cholestatic liver diseases that occur in children and others, and is a healthcare stock pursuing label expansions and additional pipeline programs. Its core treatment's sales and label expansions are the key drivers of value.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded about as much as usual. That is 94% of its average volume.
Next earnings report: November 3
3 days to go.
MIRM has a sound balance sheet but weak earning power
Of every $100 in sales, $14.76 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -3117.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $893. Peers typically go for $1,560.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +435.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 94.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #47 of 597 in the industry
Based on market cap of $6B.
MANE#45 Veradermics Inc $6B PER - 
CGON#46 Cg Oncology Inc $6B PER - MIRM#47 Mirum Pharmaceuticals Inc $6B PER - 
COGT#48 Cogent Biosciences Inc $5B PER - 
SRRK#49 Scholar Rock Holding Corp $5B PER - 
FAQ
What kind of company is MIRM?
MIRM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MIRM?
The market cap of MIRM is approximately $5.5B, ranking 1,293 within its sector.
What is the 52-week high and low for MIRM?
MIRM has recorded a 52-week high of $130.00 and a low of $63.23.
